Association between sirolimus trough concentration and clinical outcomes during maintenance therapy after kasabach-merritt phenomenon remission in kaposiform hemangioendothelioma: a pilot exploratory study

Background Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that may be complicated by Kasabach-Merritt phenomenon (KMP), a life-threatening consumptive coagulopathy syndrome. Although sirolimus has improved clinical outcomes, the optimal trough concentration during maintenance therapy after KMP remission remains unclear. This study aimed to evaluate the efficacy and safety associated with varying sirolimus exposure during the 12-month maintenance phase. Methods We retrospectively reviewed 26 patients with KHE who achieved KMP remission and received sirolimus maintenance therapy for at least 12 months. Patients were classified according to their average maintenance-phase sirolimus trough concentration into low exposure group (4∼8 ng/mL, n = 14) and high exposure group (8∼15 ng/mL, n = 12). Lesion regression, KMP recurrence, and treatment-related adverse events (AEs) were compared between groups. Multivariate Firth-corrected Logistic regression was applied for exploratory analysis of factors associated with KMP recurrence. To avoid reverse causation, only trough concentrations obtained prior to KMP recurrence were included in the regression models; measurements collected after recurrence were excluded. Results Baseline characteristics were comparable between the two groups. Both groups achieved progressive lesion regression during maintenance therapy. The high exposure group showed a significantly higher regression rate at 3 months; however, no significant differences were observed at 6 or 12-months follow-ups. In this small cohort, no statistically detectable difference in the frequency of sirolimus-related AEs was observed across exposure groups. Numerically, KMP recurrence was less common in the high exposure group (p = 0.036). In the exploratory multivariate analysis adjusting for clinical confounders, higher sirolimus exposure prior recurrence showed a protective trend against KMP recurrence but was not statistically significant (OR = 0.071, 95% CI = 0.003∼1.601, p = 0.096). Conclusion This exploratory analysis demonstrated that varying sirolimus exposure achieves comparable efficacy and safety within the 12 months maintenance phase among patients with KHE after KMP remission. High sirolimus exposure may accelerate early lesion regression and potentially reduce recurrence risk, although an independent protective benefit remains unconfirmed. Individualized sirolimus maintenance strategies guided by disease trajectory and therapeutic drug monitoring may be preferable to routine targeting of high trough concentrations.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.2002911
Primary Topic
Vascular Malformations and Hemangiomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between sirolimus trough concentration and clinical outcomes during maintenance therapy after kasabach-merritt phenomenon remission in kaposiform hemangioendothelioma: a pilot exploratory study

Xiaohong Die, HOU Jinping, Yun He, Wei Feng et al.
1 links
Frontiers in Pharmacology
Vascular Malformations and Hemangiomas
article

Association between sirolimus trough concentration and clinical outcomes during maintenance therapy after kasabach-merritt phenomenon remission in kaposiform hemangioendothelioma: a pilot exploratory study

Xiaohong Die, HOU Jinping, Yun He, Wei Feng, Yi Wang, Zhenhua Guo, Wei Liu
article en

Abstract

Background Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that may be complicated by Kasabach-Merritt phenomenon (KMP), a life-threatening consumptive coagulopathy syndrome. Although sirolimus has improved clinical outcomes, the optimal trough concentration during maintenance therapy after KMP remission remains unclear. This study aimed to evaluate the efficacy and safety associated with varying sirolimus exposure during the 12-month maintenance phase. Methods We retrospectively reviewed 26 patients with KHE who achieved KMP remission and received sirolimus maintenance therapy for at least 12 months. Patients were classified according to their average maintenance-phase sirolimus trough concentration into low exposure group (4∼8 ng/mL, n = 14) and high exposure group (8∼15 ng/mL, n = 12). Lesion regression, KMP recurrence, and treatment-related adverse events (AEs) were compared between groups. Multivariate Firth-corrected Logistic regression was applied for exploratory analysis of factors associated with KMP recurrence. To avoid reverse causation, only trough concentrations obtained prior to KMP recurrence were included in the regression models; measurements collected after recurrence were excluded. Results Baseline characteristics were comparable between the two groups. Both groups achieved progressive lesion regression during maintenance therapy. The high exposure group showed a significantly higher regression rate at 3 months; however, no significant differences were observed at 6 or 12-months follow-ups. In this small cohort, no statistically detectable difference in the frequency of sirolimus-related AEs was observed across exposure groups. Numerically, KMP recurrence was less common in the high exposure group (p = 0.036). In the exploratory multivariate analysis adjusting for clinical confounders, higher sirolimus exposure prior recurrence showed a protective trend against KMP recurrence but was not statistically significant (OR = 0.071, 95% CI = 0.003∼1.601, p = 0.096). Conclusion This exploratory analysis demonstrated that varying sirolimus exposure achieves comparable efficacy and safety within the 12 months maintenance phase among patients with KHE after KMP remission. High sirolimus exposure may accelerate early lesion regression and potentially reduce recurrence risk, although an independent protective benefit remains unconfirmed. Individualized sirolimus maintenance strategies guided by disease trajectory and therapeutic drug monitoring may be preferable to routine targeting of high trough concentrations.

Frontiers in PharmacologyVol. 17
Sichuan University (CN), West China Second University Hospital of Sichuan University (CN), Children's Hospital of Chongqing Medical University (CN), Chongqing Medical University (CN)
Good health and well-being
Vascular Malformations and Hemangiomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon